Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first...
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program – Financing Round Led by Viking Global Investors – – Proceeds will fund ongoing clinical development of EDG-5506, a novel, oral drug candidate...
Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy – EDG-5506 is a novel, oral, small molecule drug candidate with the potential to promote muscle function in patients with muscular dystrophy – Boulder, Colo., (November 11,...
Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting – Preliminary Results Showed 41% (9 of 22 Patients) Objective...
Kit Check and Sandoz Collaborate to Launch RFID-tagged Generic Injectables in October 2020 DoseID members, Kit Check and Sandoz, have agreed to launch RFID-tagged injectable medicines Two NDCs of Sandoz RFID-tagged medicines will be available in October 2020, with...
TigerConnect Acquires Call Scheduler, Launches Fully-Integrated TigerSchedule™ to Simplify Physician On-Call Scheduling Acquisition bolsters collaboration across complex healthcare teams to drive efficiency in the COVID-19 era SANTA MONICA, Calif. — Sept. 1, 2020 —...
Recent Comments